JP2024521811A5 - - Google Patents

Info

Publication number
JP2024521811A5
JP2024521811A5 JP2023573116A JP2023573116A JP2024521811A5 JP 2024521811 A5 JP2024521811 A5 JP 2024521811A5 JP 2023573116 A JP2023573116 A JP 2023573116A JP 2023573116 A JP2023573116 A JP 2023573116A JP 2024521811 A5 JP2024521811 A5 JP 2024521811A5
Authority
JP
Japan
Prior art keywords
peptide
cells
seq
inhibiting
envelope glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521811A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031459 external-priority patent/WO2022251712A1/en
Publication of JP2024521811A publication Critical patent/JP2024521811A/ja
Publication of JP2024521811A5 publication Critical patent/JP2024521811A5/ja
Pending legal-status Critical Current

Links

JP2023573116A 2021-05-28 2022-05-27 短縮型ヒヒ内在性レトロウイルス(BaEV)エンベロープ糖タンパク質を含む脂質粒子、ならびに関連する方法及び使用 Pending JP2024521811A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194880P 2021-05-28 2021-05-28
US63/194,880 2021-05-28
PCT/US2022/031459 WO2022251712A1 (en) 2021-05-28 2022-05-27 Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses

Publications (2)

Publication Number Publication Date
JP2024521811A JP2024521811A (ja) 2024-06-04
JP2024521811A5 true JP2024521811A5 (enExample) 2025-06-03

Family

ID=82851603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573116A Pending JP2024521811A (ja) 2021-05-28 2022-05-27 短縮型ヒヒ内在性レトロウイルス(BaEV)エンベロープ糖タンパク質を含む脂質粒子、ならびに関連する方法及び使用

Country Status (8)

Country Link
US (1) US20240254168A1 (enExample)
EP (1) EP4347620A1 (enExample)
JP (1) JP2024521811A (enExample)
CN (1) CN117642420A (enExample)
AU (1) AU2022280957A1 (enExample)
CA (1) CA3219487A1 (enExample)
IL (1) IL308836A (enExample)
WO (1) WO2022251712A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
JP2024532963A (ja) 2021-04-08 2024-09-11 サナ バイオテクノロジー,インコーポレイテッド Cd8特異的抗体コンストラクト及びその組成物
CN113608287B (zh) * 2021-08-06 2023-06-02 暨南大学 一种微透镜及其应用
US20250082777A1 (en) * 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4602174A1 (en) * 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024254346A1 (en) * 2023-06-07 2024-12-12 The Broad Institute, Inc. Engineered viral like particles (evlps) for the selective transduction of target cells
WO2024259051A1 (en) * 2023-06-14 2024-12-19 The Children's Medical Center Corporation Systems and methods for modifying a polynucleotide
CN119264228B (zh) * 2023-07-04 2025-11-25 清华大学 一种具有广泛细胞嗜性和高效感染效率的包膜蛋白及其应用
TW202540399A (zh) * 2023-11-14 2025-10-16 中央研究院 用於有效包裹病毒顆粒之經修改的細胞株
CN119020418B (zh) * 2024-08-17 2025-06-13 广东君厚生物医药有限公司 BaEV逆转录病毒载体的包装方法及其包装细胞系
CN122012416A (zh) * 2026-04-14 2026-05-12 山东丽山生物科技有限公司 一种提高慢病毒滴度的方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
WO1999032646A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2011058052A1 (en) 2009-11-13 2011-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Direct protein delivery with engineered microvesicles
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
US9249426B2 (en) * 2011-09-29 2016-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vectors pseudotyped with mutant BaEV glycoproteins
WO2013148327A1 (en) 2012-03-26 2013-10-03 The Regents Of The University Of California Nipah virus envelope psuedotyped lentiviruses and methods of their use
EP3415627A1 (en) 2012-11-13 2018-12-19 Codiak BioSciences, Inc. Delivery of therapeutic agent
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
WO2016077639A2 (en) 2014-11-12 2016-05-19 VL27, Inc. Nanovesicular therapies
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2017005923A1 (en) * 2015-07-09 2017-01-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vector expressing membrane-anchored or secreted antibody
US20180291080A1 (en) 2015-09-28 2018-10-11 Trustees Of Dartmouth College Chimeric antigen receptor, regulatory cells and methods of use
EP3858388B1 (en) 2015-09-28 2024-07-03 Regents of the University of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd
JP7059179B2 (ja) 2015-10-20 2022-04-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子操作のための方法及び製品
US20170151287A1 (en) 2015-11-30 2017-06-01 Flagship Ventures Management, Inc. Methods and compositions of chondrisomes
SG10202008883SA (en) 2016-03-15 2020-10-29 Codiak Biosciences Inc Therapeutic membrane vesicles
US11325948B2 (en) * 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
CN111328290A (zh) 2017-06-26 2020-06-23 博德研究所 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
EP3720502A4 (en) 2017-12-07 2022-01-19 Flagship Pioneering Innovations V, Inc. CYTOBIOLOGICS AND THERAPEUTIC USES THEREOF
EP3728576A4 (en) 2017-12-22 2021-11-24 The Broad Institute, Inc. CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF RNA BASES
WO2019126762A2 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
US20230193242A1 (en) 2017-12-22 2023-06-22 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
WO2019157319A1 (en) 2018-02-12 2019-08-15 Flagship Pioneering Innovations V, Inc. Devices and methods for delivering material into a biological tissue or cell
BR112020016570A2 (pt) 2018-02-17 2020-12-15 Flagship Pioneering Innovations V, Inc. Composições e métodos para liberação de proteína de membrana
CN112367973A (zh) 2018-05-15 2021-02-12 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
CA3105953A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
US20230048166A1 (en) 2018-11-14 2023-02-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
EP3880179A2 (en) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
KR20210131991A (ko) 2018-11-14 2021-11-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 구획-특이적 카고 전달을 위한 조성물 및 방법
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20230235309A1 (en) 2020-02-05 2023-07-27 The Broad Institute, Inc. Adenine base editors and uses thereof
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CA3193099A1 (en) 2020-09-24 2022-03-31 David R. Liu Prime editing guide rnas, compositions thereof, and methods of using the same

Similar Documents

Publication Publication Date Title
US10829785B2 (en) Nucleic acid application primers
CA3105953A1 (en) Fusosome compositions and uses thereof
US7090837B2 (en) Compositions and methods for tissue specific targeting of lentivirus vectors
US20240401077A1 (en) Koala retrovirus envelope gylcoproteins and uses thereof
US7135339B2 (en) Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
US5929222A (en) Expression of a foamy virus envelope protein
Yajima et al. Retroviral vector targeting human cells via c-Kit–stem cell factor interaction
Stitz et al. A novel lentivirus vector derived from apathogenic simian immunodeficiency virus
US6277601B1 (en) Expression of a foamy virus envelope protein
US6132731A (en) Murine leukemia virus vectors
US9840720B2 (en) Materials and methods relating to packaging cell lines
KR20230154075A (ko) 세포 및 유전자 치료를 위한 바이러스 벡터 생성자 세포를 생성하고 최적화하기 위한 조성물 및 방법
Tolmachov et al. Designing lentiviral gene vectors
Miyake et al. Selective killing of human immunodeficiency virus-infected cells by targeted gene transfer and inducible gene expression using a recombinant human immunodeficiency virus vector
ES2236888T3 (es) Expresion de una proteina modificada de la envoltura del virus espumoso.
US6150138A (en) Expression of a foamy virus envelope protein
KR100969271B1 (ko) 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합 발현 벡터 시스템
US6703226B1 (en) Expression of a foamy virus envelope protein
Schambach et al. Retroviral vectors for cell and gene therapy
JP2026511127A (ja) 発現コンストラクト
Pages et al. Retrovectors go forward
van Heuvel Optimization of retroviral packaging cells for scale-up of vector production
KR100969268B1 (ko) 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합 발현 벡터 시스템
Kleff et al. Comparison of Different Transient Retroviral Transfection Systems
Manual Platinum ES/EC Retrovirus Expression System, Ecotropic